Back to search results

GSK5926371 for Relapsed or Refractory B-NHL

This study is testing a drug called GSK5926371 in adults with B-cell non-Hodgkin lymphoma (B-NHL), a type of blood cancer, that has come back or didn't respond to previous treatments. The main goals are to see how safe GSK5926371 is and what side effects it might cause. Researchers also want to understand how well the drug works and how it moves through the body. You may be able to join if you are an adult with B-NHL that has returned or resisted at least two prior treatments, including one with an anti-CD20 medicine. The study plans to enroll 49 participants, but its current status is unclear.

Study design
This is an interventional study with a planned enrollment of 49 adult participants. GSK5926371 will be given at different dose levels.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for adverse events for up to approximately 169 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07607925

A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL

Not Yet Recruiting
PHASE1Ages 18+InterventionalTreatment
GlaxoSmithKline
~49 participants
Updated 2026-06-18 on ClinicalTrials.gov
What's tested:GSK5926371

At a glance

Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with dose limiting toxicities (DLTs)
Measured over Up to 28 days
+1 more outcome measured

Conditions

Lymphoma, Non-Hodgkin

Explore related trials

B-Cell Non-Hodgkin Lymphoma

NCT07607925

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • GSK Investigational Site

    Canton, Ohiostudy coordinator listed

  • GSK Investigational Site

    Toronto, Ontario, Canadastudy coordinator listed

  • GSK Investigational Site

    Tokyo, Japanstudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

US GSK Clinical Trials Call Center
[email protected]
877-379-3718
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Has histologically confirmed Relapsed/Refractory (R/R) B-NHL, for which systemic treatment is indicated,
Willing to use adequate contraception (Participant of childbearing potential \[POCBP\] only).
Is capable of giving signed informed consent
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
Has adequate organ function.

Exclusion

Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas (e.g., breast, cervix, bladder) that have been resected with no evidence of metastatic disease.
Has had any major surgery within 4 weeks prior to the first dose of GSK5926371 or has not recovered from prior surgeries or complications.
Has a history of Progressive multifocal leukoencephalopathy (PML), current central nervous system (CNS) involvement by lymphoma, or a history of significant CNS disease such as uncontrolled seizures, stroke, epilepsy, CNS vasculitis, and neurodegenerative conditions.
Has an active uncontrolled infection.
Has received a prior Allogeneic stem cell transplant (allo-SCT) within 12 months prior to the first dose of GSK5926371 or has active graft-versus-host disease requiring systemic immunosuppressive therapy.
Has received a prior autologous stem cell transplant within 100 days prior to the first dose of GSK5926371.
Has received prior treatment with Chimeric antigen receptor T-cell (CAR-T) therapy within 12 weeks of first GSK5926371 administration.
Has received prior treatment with CD19- or CD20-targeting Bispecific antibody (BsAbs) within 8 weeks of the first dose of study intervention.
Has QT interval corrected (QTc) \>450 milliseconds (msec) or QTc \>480 msec for participants with bundle branch block.
Has significant cardiovascular disease such as uncontrolled arrhythmias, Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification, ejection fraction \<=45% by any methods in the 12 months of enrollment, unstable angina or acute coronary syndrome including myocardial infarction within 6 months of enrollment.

What this trial measures

  • Number of participants with dose limiting toxicities (DLTs)Up to 28 days
  • Number of participants with adverse events (AEs) or Serious adverse events (SAEs) by severityUp to approximately 169 weeks